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Abstract
Background
Chronic infection with hepatitis B or C virus (HBV/HCV) can progress to cirrhosis, liver can-
cer, and even death. In a low endemic country as the Netherlands, migrants are a key risk
group and could benefit from early diagnosis and antiviral treatment. We assessed the cost-
effectiveness of screening foreign-born migrants for chronic HBV and/or HCV using a socie-
tal perspective.
Methods
The cost-effectiveness was evaluated using a Markov model. Estimates on prevalence,
screening programme costs, participation and treatment uptake, transition probabilities,
healthcare costs, productivity losses and utilities were derived from the literature. The cost
per Quality Adjusted Life Year (QALY) gained was estimated and sensitivity analyses were
performed.
Results
For most migrant groups with an expected high number of chronically infected cases in the
Netherlands combined screening is cost-effective, with incremental cost-effectiveness
ratios (ICERs) ranging from €4,962/QALY gained for migrants originating from the Former
Soviet Union and Vietnam to €9,375/QALY gained for Polish migrants. HBV and HCV
screening proved to be cost-effective for migrants from countries with chronic HBV or HCV
prevalence of�0.41% and�0.22%, with ICERs below the Dutch cost-effectiveness
PLOS ONE | https://doi.org/10.1371/journal.pone.0207037 November 8, 2018 1 / 16
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Suijkerbuijk AWM, van Hoek AJ, Koopsen
J, de Man RA, Mangen M-JJ, de Melker HE, et al.
(2018) Cost-effectiveness of screening for chronic
hepatitis B and C among migrant populations in a
low endemic country. PLoS ONE 13(11):
e0207037. https://doi.org/10.1371/journal.
pone.0207037
Editor: Isabelle Chemin, Centre de Recherche en
Cancerologie de Lyon, FRANCE
Received: July 30, 2018
Accepted: October 23, 2018
Published: November 8, 2018
Copyright: © 2018 Suijkerbuijk et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
reference value of €20,000/QALY gained. Sensitivity analysis showed that treatment costs
influenced the ICER for both infections.
Conclusions
For most migrant populations in a low-endemic country offering combined HBV and HCV
screening is cost-effective. Implementation of targeted HBV and HCV screening pro-
grammes to increase early diagnosis and treatment is important to reduce the burden of
chronic hepatitis B and C among migrants.
Introduction
People with chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection are at
risk of serious illness and death from liver disease, such as liver cirrhosis and hepatocellular
carcinoma [1]. Transmission of HBV can occur vertically (mother-to-child), horizontally, and
via sexual or blood contact, while HCV is mainly transmitted via blood contact [2]. The risk of
developing chronic HBV infection is highly age dependent; 90% of infants infected at birth
develop later in life a chronic infection, compared to less than 10% of those infected as adults
[3]. Infection with HCV results in a chronic infection in 50–80% of patients [4]. Patients with
chronic hepatitis B (CHB) or C (CHC) can eventually develop cirrhosis (up to 50%) and liver
cancer (1–5%) over a period of 20–30 years [4, 5].
Effective antiviral treatment is available for CHB and can achieve long-term viral suppres-
sion in up to 94% of patients [5]. More recently, the treatment options for CHC have greatly
improved through the introduction of direct acting antiviral therapy (DAAs), that shows cure
rates of over 95% [6] and is, since November 2015, reimbursed by the basic healthcare insur-
ance in the Netherlands for all CHC patients, independent of the stage of liver disease.
To prevent hepatitis-related burden of disease and death, timely diagnosis and linkage to
care for treatment of eligible patients is needed [7]. However, this is challenging as many
patients with chronic viral hepatitis experience no or few clinical symptoms before major com-
plications (development of ascites, variceal bleeding, hepatocellular carcinoma (HCC) occur.
Therefore, active case finding through screening is required.
The prevalence in the Dutch general population is low; estimated at 0.3% for chronic HBV
and 0.1% for chronic HCV infections [8]. In a low endemic setting like the Netherlands,
migrants originating from endemic regions are an important risk group and are estimated to
account for 81% of chronic HBV and 60% of chronic HCV infections [9–11]. The Dutch
Health Council advised in 2016 to offer screening for HBV and/or HCV to migrants from
countries with a prevalence of chronic HBV or HCV of�2% [8]. To inform the implementa-
tion of targeted screening interventions we estimated the cost-effectiveness of screening for-
eign-born migrants for HBV, for HCV, and of combined HBV and HCV screening in the
Netherlands.
Methods
Model
We investigated the cost-effectiveness of screening foreign-born migrants per country of ori-
gin using a Markov model programmed in MS Excel 2010. CHEERS guidelines for reporting
economic evaluations were followed [12]. A lifelong time horizon was considered. The benefit
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of the screening programme is early detection of those who are prone to develop complications
later in life, where antiviral treatment prevents disease progression, with associated quality of
life advantages and cost reductions, as well as increased survival. The lifetime costs and Qual-
ity-Adjusted Life Years (QALYs) were calculated for a 40 year old person, based on the average
age of migrants participating in several pilot screening projects performed in the Netherlands
[13–16]. We present costs and clinical impact of HBV and HCV screening. The incremental
cost-effectiveness ratio (ICER) of a HBV or HCV programme was calculated using no screen-
ing as comparator strategy. For a combined screening programme the ICER was first calcu-
lated for adding HCV testing to an HBV programme, and vice versa depending on the most
cost-effective strategy. In addition, we performed country-specific threshold analysis to
retrieve the maximum investment per migrant allowed, given the prerequisite that the cost-
effectiveness level of €20,000 per QALY should not be exceeded. This value is considered an
acceptable value for cost-effectiveness in the Netherlands [17]. The cost-effectiveness model
was performed from a societal perspective, including an impact on productivity of those
infected. Cost and QALYs were discounted differently, costs with 4% and health benefits with
1.5%, following Dutch guidelines [18].
Hepatitis B
Disease states considered for HBV infection were undiagnosed inactive chronic infection,
diagnosed inactive chronic infection, delayed clearance, CHB, compensated cirrhosis, decom-
pensated cirrhosis, hepatocellular carcinoma (HCC), liver transplantation, hepatitis related
death, and non-hepatitis related death (for a description of the disease states see S1 Table and
S1 Fig). The annual transition rates for individuals experiencing natural disease progression
and for those undergoing early treatment were taken from the literature and are shown in S2
Table. We assumed that all those with decompensated cirrhosis or HCC will seek medical care
and have a known HBV status. The screening procedure and follow-up is described in supple-
mentary S1 Text. In the initial screening test, 10% of those tested HBsAg positive were classi-
fied as CHB patients [19]. The remaining 90% had inactive chronic HBV infection.
Hepatitis C
Disease states for HCV infection were CHC, compensated cirrhosis, decompensated cirrhosis,
HCC, liver transplant, hepatitis-related death and non-hepatitis related death (see S1 Table
and S2 Fig). The annual transition rates for individuals experiencing natural disease progres-
sion and for those undergoing treatment were taken from the literature and are given in S2
Table. Based on Helsper et al., it was assumed that 11% of CHC patients have compensated cir-
rhosis.[20] Patients with more severe disease end points, (i.e. decompensated cirrhosis and
HCC), were assumed to seek medical care based on impaired health status, and got diagnosed
and treated. The screening procedure and follow-up is described in S1 Text.
Migrant population size and chronic HBV and HCV prevalence
Foreign-born migrant populations registered in the Municipal Personal Records database
(BRP) in the Netherlands on 1-1-2016 (www.statline.nl) were included by country of birth for
populations with at least 500 first generation migrants (aged 15 or over), see S3 and S4 Tables.
In the Netherlands, asylum seekers and refugees are registered in the BRP within six months
after arrival. As a consequence, unregistered foreign-born migrants and migrants coming
from countries with less than 500 first generation migrants living in the Netherlands were
excluded. The prevalence of chronic infections with HBV or HCV by country of birth was
recently obtained from a review of the (un)published literature on prevalence in migrant
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populations in the Netherlands or, in absence of data, in countries of origin [11]. Migrant
groups with an HBsAg prevalence estimate of at least 1% for HBV [21] and/or HCV-RNA
prevalence of at least 0.5% for HCV in the country of origin were included [11, 22].
Baseline testing rate and background mortality
In absence of a specific screening programme we assumed that 2.2% of the cohort migrants
would be tested and diagnosed annually for HBV and 2.0% for HCV for other reasons such as
pregnancy screening (HBV only), as part of STI testing or due to complaints. For HBV this
was based on 900 newly diagnosed chronic HBV infections among foreign-born migrants in
2016 (notification data), of an estimated total of 40,000 chronic HBV infections in this group
[11]. For HCV 500 chronic HCV diagnosis were reported by virological laboratories in 2016 of
which ~60% were assumed to be foreign-born migrants (~300 cases) divided by an estimated
14,000 cases with chronic HCV infection among migrants [11, 23].
Background mortality for causes of death other than HBV and HCV disease was calculated
using age-specific Dutch population averages retrieved from Statistics Netherlands [24].
Migrants, although born elsewhere, were assumed to have the Dutch background mortality
rate.
Participation in the screening programme
On the basis of experiences with earlier Dutch pilot screening programmes targeting migrants
originating from Afghanistan, Iran, Iraq, the former Soviet Republics, Vietnam, China, and
Egypt we assumed that 30% of all invited migrants would participate in the screening pro-
gramme [14, 15, 25, 26]. Based on a Dutch retrospective analysis of follow-up diagnostics and
referrals to secondary care after diagnosis of a hepatitis B or C infection in general practice and
on data from screening interventions targeting Chinese migrants, we assumed that 80% of
individuals that test positive would be effectively linked to care for clinical follow-up and treat-
ment and the other 20% would experience natural disease progression [13, 27].
Quality of life
Utility values to determine loss of quality of life in patients being chronically infected were
derived from Stahmeijer et al [28] (Table 1). Given being in a certain health state, we assumed
equal utility losses for HBV and HCV disease states, as both infections imply the same course
of the disease except for having an inactive chronic infection, a health state only related to
HBV.
Costs
Cost estimates were determined for medical care, productivity losses, and programme imple-
mentation and administration (Table 1 and S5 Table) and are explained in detail in S1 Text.
Clinical management costs for inactive chronic HBV infection and for CHB patients were esti-
mated using resource use based on clinical guidelines [5] and, following Dutch guidelines for
economic evaluations in health care [18], multiplying resource use with Dutch references
prices as presented in Table 1. We assumed similar healthcare costs for HCC and liver trans-
plant for both HBV and HCV, as the clinical symptoms and treatment options are similar, irre-
spective of the original infection. Loss of productivity for CHB and CHC patients, up to 65
years of age was retrieved from Scalone et al. [33]. The sick leave length was multiplied by the
average hourly wage adjusted for the employment rate in several age groups of migrants origi-
nating from non-western countries (Table 1) [18]. The costs of the screening programme
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Table 1. Overview of the costs of the screening programme, utilities and costs of HBV and HCV disease and treatment in Euro (2016).
Hepatitis B Source Hepatitis C Source
Programme costs (in €) per person approached
37 [29] 37 [29]
Test costs (in €) per person screened
Order tariff 11 [30] 11 [30]
Test costs (HBsAg/anti-HCV) 10 [30] 10 [30]
Total test costs 21 21
Additional costs (in €) if positive
Outpatient visit 91 [18] 91 [18]
Order tariff 11 [30] 11 [30]
PCR 178 [30] 178 [30]
HBeAg 10 [30] -
ALT 2 [30] -
Fibroscan 103 [30] 103 [30]
Total additional costs 394 382
Annual healthcare costs (in €)
Inactive chronic infection 224 Own calculationsa - -
CHB/ CHC 5386 Own calculationsa 211 [31]
Compensated cirrhosis 6670 [32] 437 [31]
Decompensated cirrhosis 28,170 [31] 28,170 [31]
HCC 21,592 [31] 21,592 [31]
Liver transplantation 264,446 [32]b 264,446 [32]b
Costs (in €) including treatment DAA once only
CHC - - 48,044 Own calculationsa
Compensated cirrhosis - - 48,044 Own calculationsa
Decompensated cirrhosis - - 48,044 Own calculationsa
Annual costs (in €) after treatment with DAAs
CHC - - 205 [31]
Compensated cirrhosis - - 501 [31]
Decompensated cirrhosis - - 501 [31]
Productivity losses
Annual number of work days lost
CHB/CHC (days) 8.4 [33] 13.2 [33]
Cirrhosis 15.6 [33] 25.2 [33]
HCC 18 [33] 27.6 [33]
Liver transplantation 26.4 [33] 38.4 [33]
Employment rate
35–45 years 0.64 [34] 0.64 [34]
45–55 years 0.63 [34] 0.63 [34]
55–65 years 0.48 [34] 0.48 [34]
Mean costs per working hour
40–44 years 40.04 [35] 40.04 [35]
45–49 years 41.20 [35] 41.20 [35]
50–54 years 41.61 [35] 41.61 [35]
55–59 years 41.83 [35] 41.83 [35]
60–64 years 41.30 [35] 41.30 [35]
Utility values
Inactive chronic infection 1 assumption -
(Continued)
Cost-effectiveness screening migrant populations for chronic hepatitis B and C
PLOS ONE | https://doi.org/10.1371/journal.pone.0207037 November 8, 2018 5 / 16
included laboratory test costs as obtained from the Dutch Healthcare Authority [30], follow-
up costs for an ultrasonography including fibroscan, and consulting clinicians based on refer-
ence prices from the National Health Care Institute [18]. Overall programme costs were esti-
mated at €37 per person approached and included educating general practitioner (GPs),
practice nurses, and Municipal Health Service (MHSs) staff, sending invitational letters to
migrants, providing information in different languages on websites and in leaflets. All costs
are indexed to Euros 2016
Sensitivity and scenario analysis
To identify the most relevant uncertainties of our outcomes a one-way sensitivity analysis was
performed. All input parameters in the model were decreased and increased with 25% and the
ten most important ones are plotted in a tornado diagram. Furthermore, a number of scenario
analyses were performed. For international comparison we applied a 3% discount rate for both
costs and effects. Additionally, we changed screening participation from 30% to 20% and 40%,
we changed the background mortality for the general population with the mortality for
migrants originating from a non-western country [36], and we excluded productivity losses
from the model. Finally, we assessed results for lower participation rates in combination with
higher screening costs.
Results
The clinical impact of screening ten migrant populations with the expected highest number of
chronic HBV and ten migrant populations with the expected highest number of chronic HCV
infections in the Netherlands is presented in Table 2, resulting in results for 16 countries as
four countries had a relatively high number of both chronic HBV and HCV cases. These were
Surinam, Vietnam, the former Soviet Union and Indonesia. The largest number of complica-
tions due to HBV-infection can be prevented by screening migrants born in Turkey, with an
estimated number of 7,463 chronically infected cases in the Netherlands (S3 Table). The largest
number of HCV complications can be averted by screening and treating migrants born in Sur-
inam, with an estimated number of 2,935 chronically infected cases in the Netherlands (S4
Table).
For most countries listed in Table 3 combining HBV and HCV screening is expected to be
the most cost-effective strategy, with ICERs ranging from €4,962/QALY gained for migrants
originating from the Former Soviet Union and Vietnam to €9,375/QALY gained for Poland.
For those countries, solitary HBV or HCV screening is dominated as, compared to combined
screening, for these strategies the costs per QALY gained are higher. For migrants originating
Table 1. (Continued)
Hepatitis B Source Hepatitis C Source
CHB/CHC 0.81 [28] 0.81 [28]
Compensated cirrhosis 0.74 [28] 0.74 [28]
Decompensated cirrhosis 0.72 [28] 0.72 [28]
HCC 0.72 [28] 0.72 [28]
Liver transplant 0.72 [28] 0.72 [28]
Post-liver transplant 0.79 [28] 0.79 [28]
a see S5 Table for details
b including 10 year follow-up costs
https://doi.org/10.1371/journal.pone.0207037.t001
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from Turkey, screening only for HBV is the most cost-effective strategy. Adding HCV on top
of HBV screening results in an ICER for HCV related costs and QALYs just above the Dutch
threshold of €20,000 per QALY gained. HCV screening only is the most cost-effective option
for migrants originating from Pakistan. However, extending HCV screening with HBV results
in an ICER of around €5,000/ HBV related QALY gained, which is below the Dutch threshold.
The ICER for combined screening was only marginally less beneficial compared to single
HCV screening. The ICERs shown in Table 3 include default programme costs of €37 per per-
son approached. Leaving these programme costs out of the model, the maximum investments
allowed to arrive at an intervention which cost-effectiveness does not exceed the Dutch thresh-
old of €20,000 per QALY gained can be calculated and is presented in Fig 1. More resource
intensive strategies, i.e. higher program costs than €37 per participant, can be used for screen-
ing programmes targeting migrants from several African countries. For instance, combined
screening of Somali migrants is still a cost-effective intervention at programme costs as high as
€1,697 per migrant.
Considering the Dutch reference value for cost-effectiveness, screening migrant groups for
HBV has a cost-effectiveness level below €20,000/QALY at an HBV prevalence of 0.41%. HCV
screening is cost-effective at a prevalence of 0.22%, taking the same threshold for cost-effec-
tiveness into account. If we would perform combined screening of the total migrant
Table 2. Averted cases of compensated cirrhosis, decompensated cirrhosis, HCC, liver transplant, and death over a life time period compared to no screening pro-
gramme for the ten countries of origin with the expected highest number of infected HBV and HCV cases in the Netherlandsa.
Hepatitis B Hepatitis C
Country of
origin
Infection with
high number of
cases
Chronic
HBV
Comp.
cirrhosis
Dec.
cirrhosis
HCC Liver
transplant
Death Chronic
HCV
Comp.
cirrhosis
Dec.
cirrhosis
HCC Liver
transplant
Death
1. Turkey HBV 739 333 91 262 80 412 11 4 2 2 0 2
2. Somalia HBV 325 147 40 116 35 182 25 8 4 4 0 4
3. China HBV 256 115 32 91 28 143 26 8 4 4 0 4
4. F.
Yugoslavia
HBV 196 88 24 70 21 109 91 30 14 14 0 13
5. Surinam HBV and HCV 178 80 22 63 19 99 597 195 91 89 0 85
6. Indonesia HBV and HCV 156 70 19 55 17 89 106 35 16 16 0 15
7. F. Soviet
Union
HBV and HCV 156 70 19 55 17 87 229 75 35 34 0 33
8. Vietnam HBV and HCV 96 43 12 34 10 53 57 19 9 9 0 8
9. Cape
Verde
HBV 94 43 12 34 10 53 30 10 5 4 0 4
10. Romania HBV 94 43 12 33 10 53 76 25 12 11 0 11
11. Morocco HCV 89 40 11 32 10 50 284 93 43 42 0 40
12. Syria HCV 75 34 9 27 8 42 138 45 21 21 0 20
13. Poland HCV 45 20 6 16 5 25 109 36 17 16 0 16
14. F. Dutch
Antilles
HCV 19 9 2 7 2 11 97 32 15 14 0 14
15. Italy HCV 63 28 8 22 7 35 87 28 13 13 0 12
16. Pakistan HCV 31 14 4 11 3 17 77 25 12 12 0 11
Comp. = compensated, dec. = decompensated, HCC = hepatocellular carcinoma, F. = former, for Yugoslavia born before 1991, for Dutch Antilles born before 2010, and
for the Soviet Union born before 1991
a the number of countries does not sum up to 20 as the F. Soviet Union, Surinam, Vietnam, and Indonesia belong to the countries with the highest number of both HBV
and HCV cases in the Netherlands
https://doi.org/10.1371/journal.pone.0207037.t002
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Table 3. Incremental cost-effectiveness of screening migrant groups for the ten countries of origin with the highest number of infected HBV and HCV cases in the
Netherlandsa.
Country Δ Costs (€�1000) Δ QALYs ICER Max. investment (€�1000)b Max. investment / migrant (€)
1. Turkey HBV 32,739 5,252 6,233 79,275 421
HCV 8,408 72 dominated - -
Both 34,174 5,324 dominated 79,270 421
2. Somalia HBV 11,791 2,313 dominated 35,285 1,590
HCV 1,538 154 dominated 2,369 107
Both 12,508 2,467 5,070 37,654 1,697
3. China HBV 10,488 1,816 dominated 27,537 601
HCV 2,590 162 dominated 2,352 51
both 11,381 1,979 5,752 29,889 652
4. F. Yugoslavia HBV 8,682 1,394 dominated 21,050 423
HCV 4,279 567 dominated 8,893 179
both 11,119 1,961 5,670 29,943 601
5. Surinam HBV 13,541 1,265 dominated 18,291 104
HCV 21,601 3,722 dominated 59,367 337
both 28,620 4,988 5,738 77,658 441
6. Indonesia HBV 9,713 1,110 dominated 16,359 157
HCV 6,995 661 dominated 10,082 96
both 12,842 1,771 7,252 26,441 253
7. F. Soviet U HBV 6,968 1,108 dominated 16,723 407
HCV 7,149 1,430 dominated 22,970 559
both 12,596 2,538 4,962 39,693 965
8. Vietnam HBV 3,732 681 dominated 10,357 826
HCV 1,882 357 dominated 5,716 456
both 5,151 1,038 4,962 16,073 1,282
9. Cape Verde HBV 3,646 671 dominated 10,205 876
HCV 1,196 184 dominated 2,920 251
both 4,410 855 5,157 13,124 1,126
10. Romania HBV 3,869 670 dominated 10,155 600
HCV 2,502 471 dominated 7,547 446
both 5,744 1,141 5,034 17,702 1,045
11. Morocco HBV 10,169 634 dominated 8,673 52
HCV 13,855 1,771 dominated 27,729 166
both 17,855 2,404 7,426 36,402 218
12.Syria HBV 3,707 531 dominated 7,957 282
HCV 4,442 857 dominated 13,751 487
both 7,104 1,388 5,117 21,708 768
13. Poland HBV 6,155 319 dominated 4,218 39
HCV 7,225 682 dominated 10,413 96
both 9,387 1001 9,375 14,631 136
14. F. Dutch Ant. HBV 4,067 134 dominated 1,566 -
HCV 5,705 604 dominated 9,312 117
both 6,827 738 9,250 10,879 137
15. Italy HBV 3,187 448 dominated 6,700 265
HCV 3,129 543 dominated 8,656 343
both 5,382 990 5,435 15,357 608
16. Pakistan HBV 1,529 221 dominated 3,320 291
(Continued)
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population included in our study, i.e. those born in countries with a HBV prevalence of at least
1% and HCV prevalence of at least 0.5%, the ICER would be €5395 per QALY gained.
Sensitivity and scenario analysis
The ten most influential input parameters for HBV and HCV screening, after decreasing and
increasing the input parameters with 25% are presented in Figs 2 and 3, using Turkey and Sur-
inam as a high prevalence country for chronic HBV (4.0%) and HCV (1.7%) respectively. For
both infections treatment costs highly influenced the ICER. With respect to HBV, the QALY
loss for the CHB disease state and the transition probability from CHB to HCC and compen-
sated cirrhosis were relatively important. For HCV, the QALY loss of CHC was important. In
addition, discount rates for costs and QALYs were of significance for both infections, see sup-
plementary S6 Table. If we excluded utility losses for the disease states CHB and CHC, that is
Table 3. (Continued)
Country Δ Costs (€�1000) Δ QALYs ICER Max. investment (€�1000)b Max. investment / migrant (€)
HCV 2,306 483 4,778 7,769 682
both 3,413 704 dominated 11,088 973
a the number of countries does not sum up to 20 as the F. Soviet Union, Surinam, Vietnam, and Indonesia both belong to the countries with the highest number of HBV
and HCV cases in the Netherlands
b excluding €37 programme costs for HBV, HCV, or combined screening, F = former, for Yugoslavia born before 1991, for Dutch Antilles born before 2010, and for the
Soviet Union born before 1991
https://doi.org/10.1371/journal.pone.0207037.t003
Fig 1. Maximum investment (€2016) allowed per migrant to achieve cost-effective combined HBV/HCV
screening (results for migrants from the Former Soviet Union and born before 1991, Former Yugoslavia, born
before 1991, and Former Dutch Antilles, born before 2010, are not included in this graph).
https://doi.org/10.1371/journal.pone.0207037.g001
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assuming perfect health, the ICER increased to €7,519 for HBV and €12,605 for HCV. When
the discount rate was changed to 3%, the ICER increased to respectively €10,426 and €6,838.
Changing the background mortality and excluding productivity costs from the model, did not
have much influence on both ICERs. If we decreased the participation rate to 10% and
decreased the number of persons who will seek treatment after a positive test to 60%, the ICER
increased to €10,346 for HBV and €11,187 for HCV.
Fig 2. Sensitivity analysis for 10 most important HBV input parameters when decreasing and increasing them with 25% for Turkey,
baseline ICER: €6233/QALY.
https://doi.org/10.1371/journal.pone.0207037.g002
Fig 3. Sensitivity analysis for 10 most important HBV input parameters when decreasing and increasing them with 25% for Surinam,
baseline ICER: €5803/QALY.
https://doi.org/10.1371/journal.pone.0207037.g003
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Discussion
Screening foreign-born migrants originating from HBV and HCV endemic countries with a
seroprevalence of at least 0.41% for HBsAg and 0.22% for HCV-RNA is expected to be cost-
effective in the Netherlands. These findings are driven by the prevention of long-term disease
sequelae such as cirrhosis and HCC. For most migrant groups with an expected high number
of CHB or CHC cases in the Netherlands this means that offering combined HBV and HCV
screening is cost-effective with ICERs far below the reference value of €20,000 per QALY
gained. We observed that screening for HBV or HCV alone was more cost-effective than com-
bined screening for some migrant groups. For migrants from Turkey for instance, screening
only for HBV was the most cost-effective option. This could be expected as the prevalence esti-
mate for chronic HCV infection in Turkish migrants is 0.03%, which is well below our defined
threshold for cost-effectiveness. For migrants from Pakistan screening for HCV only was more
cost-effective than combined screening. However, the differences between the ICERS were
very small and adding HBV on top of HCV was a cost-effective strategy as well. Therefore, and
as the expected prevalence of both infections is over 2%, combined screening for Pakistani
migrants is recommended.
Only few economic evaluations targeted at screening migrant populations have been pub-
lished so far, however, none of these studies combined HBV and HCV screening. The cost-
effectiveness of screening migrants in the UK for HCV was £23,200 per QALY gained [37].
However, in this study treatment with DAAs was not included yet. Screening migrants in the
Netherlands for HBV was assessed at €8,966 per QALY gained which is in line with results
from our study despite including the newly recommended treatment option of tenofovir and
its associated costs [19]. The treatment options used in both models have comparable effective-
ness, which might explain the similar outcomes. Screening refugees for HBV in the U.S.A. was
cost-saving [38] while in Canada cost-effectiveness of screening refugees was estimated at
$40,880 [39].
Not surprisingly, we found that reducing the currently high DAA treatment costs for CHC
would reduce the ICER significantly. DAAs are highly effective in treating CHC, have a short
duration of treatment, and are generally well tolerated even in patients with advanced liver dis-
ease [40] However, these advantages come with a major increase in treatment costs and finan-
cial consequences for health budgets [41]. In some countries, for example in India and
Australia, generic DAAs are available at much lower prices [42–44]. Taking these lower prices
into account, HCV screening could even be a cost-saving intervention according to Aggarwal
et al.[42] However, in the Netherlands, the DAA patent period will last for several years and is
unlikely to be violated, as long-term agreements on drug prices between the Ministry of Health
and pharmaceutical companies have been made.
In this study, we adopted a societal perspective and included productivity losses in the
model based on estimates taken from the literature [33]. However, Scalone et al assessed work
days lost only for persons with a paid job while some persons lost their job due to disease. As a
result productivity losses are probably underestimated in our study which results in a less ben-
eficial cost-effectiveness.
As in any cost-effectiveness model, the final ICER is obtained by combining a selected set of
parameter estimates. Therefore, there is uncertainty in the final ICER due to both statistical
uncertainty in the parameter estimates, as well as due to our modelling decisions. We did not
explore the contribution of the statistical uncertainty around each parameter on the ICER but
we did explore which parameters are most influential in changing the ICER. This revealed that
the ICER was mostly affected by treatment costs and utility losses of CHB and CHC. However,
with regard to treatment costs, we included current market prices in baseline, and uncertainty
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relates primarily to the unknown lowest value of these market prices. Obviously, the ICER
would only be affected positively with a further reduction in price of medication. If we
excluded utility losses for CHB and CHC from the model, screening also remained cost-effec-
tive. Additionally, if we combined a low participation rate of only 10% with a relatively low
rate of linkage to specialist care and treatment of 60%, screening migrant populations proved
to be cost-effective. Given that even with extreme assumptions of the most influential parame-
ters the ICER was still cost-effective we are confident that our conclusions are robust.
Results of this economic evaluation are largely driven by the underlying seroprevalence esti-
mates of chronic HBV and HCV infection in the specific migrant groups. These seropreva-
lence figures have been retrieved from migrant screening projects and prevalence studies
performed in the Netherlands and if unavailable, were taken from literature [21, 22, 45]. Due
to several bias mechanisms, prevalences found in the Netherlands may be lower than in the
country of origin. Migrants are not only a very heterogeneous group between countries, but
also within countries, where migrant-groups from the same country can defer in socio-eco-
nomic status, language and culture. We could not include undocumented migrants in our
study, as numbers per country of birth are not available. However, as the total number of
undocumented migrants in the Netherlands is estimated at 35.000 individuals, which is around
2% of the migrant population included in our study, we feel this would not have changed the
results found [46].For all those reasons concerning the migrant populations, our cost-effective-
ness estimates should be interpreted as an indication.
We were not able to estimate the proportion of migrants who have already been tested in
the past. Therefore, we may have overestimated the number of people who can still benefit
from screening. Furthermore, we used an average age of 40 years, based on the average age
that was observed in several Dutch hepatitis screening projects. When the average person
screened is older, the cost-effectiveness will be less beneficial as less QALYs can be gained. A
younger age, in contrary, would result in a more cost-effective programme, presuming the
same prevalence. But this latter is questionable, at least for HBV as vaccination started in some
of these countries as early as in 2000 [7].
In our study we assumed a modest participation rate of 30% as baseline. Several interven-
tions at low cost (see supplementary section 3) can improve engagement and compliance
along the chronic viral hepatitis care continuum [47, 48]. As in most general practices only a
few patients will be eligible for screening, a close collaboration between GPs, Municipal Health
Services (MHS) and community-based organisations seems valuable in which MHSs can take
responsibility for coordinating the screening programme [13, 14, 25, 26].
WHO launched a global viral hepatitis strategy aimed at reducing mortality by 65% by
2030. To reach this target, increased efforts are needed to scale-up testing and treatment [2].
Several countries have already made progress in recent years implementing interventions tar-
geted at specific risk groups such as injecting drug users [49]. In addition, many countries
have introduced universal HBV-vaccination and global coverage in infants has increased from
around 30% in the year 2000 to over 80% in 2015. However, among migrants born before rou-
tine implementation of HBV-vaccination, the proportion of people living with chronic HBV-
infection remains high [2]. Given that migrants are disproportionately affected by chronic
viral hepatitis, both expansion of HBV and HCV screening programmes to increase early diag-
nose and improving access to effective treatment are important to reduce the burden of dis-
ease. Our results indicate cost-effectiveness of combined screening. Therefore, screening
strategies can be considered targeting foreign-born migrants with a relatively high prevalence,
not only for the Netherlands but also for other low endemic countries with a comparable
healthcare system. The current advice of the Dutch Health Council is to screen migrants from
countries with a prevalence of chronic HBV or HCV of� 2%. Only 8.2% of all foreign-born
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migrants in the Netherlands meet this threshold, and this group includes 17.6% of all expected
chronic HBV and HCV infections in the foreign-born population. When the prevalence
threshold would be lowered to a prevalence of 1% for chronic HBV and 0.5% for chronic
HCV, potentially 61.5% of all chronic infections could be detected by offering combined
screening to 40% of the foreign-born migrant population. At an ICER of €5395 per QALY
gained this strategy could reduce the HBV and HCV disease burden in a cost-effective way,
and this suggests lowering of the recommended prevalence threshold for screening should be
considered.
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